Tivozanib hydrochloride is under clinical development by AVEO Pharmaceuticals and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData, Phase II drugs for Bile Duct Cancer (Cholangiocarcinoma) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tivozanib hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tivozanib hydrochloride overview
Tivozanib Hydrochloride (Fotivda) is a quinoline urea derivative and acts as anti neoplastic agent. It is formulated as hard gelatin capsules for oral route of administration. Fotivda is indicated in the treatment of advanced (metastatic) renal cell carcinoma in adult patients and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC.
Tivozanib Hydrochloride is also under development for the treatment of soft tissue sarcoma, gallbladder cancer, neuroendocrine cancer, pancreatic adenocarcinoma, prostate cancer, renal cell carcinoma and metastatic hepatocellular carcinoma and wet age-related macular degeneration, ovarian cancer, fallopian tube cancer, peritoneal cancer and bile duct cancer (Cholangiocarcinoma). It is also administered by ocular route and oral route. It was under development for the treatment of solid tumors, breast cancer, vulvar cancer, metastatic colorectal cancer, hepatocellular cancer, non-small cell lung cancer.
AVEO Pharmaceuticals overview
AVEO Pharmaceuticals (AVEO), is a biopharmaceutical company that focuses on the discovery, development, and commercialization of drugs for the treatment of various types of cancers. Its flagship product tivozanib is approved as a first-line treatment for adult patients with renal cell carcinoma and marketed under the brand name Fotivda in European Union, Iceland and Norway. The company’s clinical product includes Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, and AV-203, an anti-ErbB3 monoclonal antibody. It also has pre-clinical products in the pipeline. The company develops products through strategic partnerships with other pharmaceutical companies. AVEO is headquartered in Boston, Massachusetts, the US.
For a complete picture of Tivozanib hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.